Achieve Life Sciences

Update in progress

ACHV (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Achieve Life Sciences, Inc. is a late-stage pharmaceutical company developing and commercializing cytisinicline to help people achieve nicotine independence in Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid that interacts with brain nicotine receptors to reduce withdrawal symptoms. The company has license and supply agreements with Sopharma AD and the University of Bristol, and is headquartered in Bothell, Washington.

Company score

Sentiment: 0.51; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.37; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.14; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.33; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationUnited States
CEODr. Andrew D. Goldberg M.D.
Employees28
Websitewww.achievelifesciences.com

Identifiers

ISINUS0044685008
FIGIBBG000FB8S62
CUSIP004468104
CIK0000949858